236 related articles for article (PubMed ID: 33051330)
21. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis.
Akturk HK; Kahramangil D; Sarwal A; Hoffecker L; Murad MH; Michels AW
Diabet Med; 2019 Sep; 36(9):1075-1081. PubMed ID: 31199005
[TBL] [Abstract][Full Text] [Related]
22. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
23. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
24. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Cho YK; Jung CH
Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
26. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitor-associated celiac disease.
Badran YR; Shih A; Leet D; Mooradian MJ; Coromilas A; Chen J; Kem M; Zheng H; Borowsky J; Misdraji J; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581063
[TBL] [Abstract][Full Text] [Related]
28. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
30. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
31. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
32. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
33. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center.
Jeun R; Iyer PC; Best C; Lavis V; Varghese JM; Yedururi S; Brady V; Glitza Oliva IC; Dadu R; Milton DR; Brock K; Thosani S
Immunotherapy; 2023 Apr; 15(6):417-428. PubMed ID: 37013834
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
Bitton K; Michot JM; Barreau E; Lambotte O; Haigh O; Marabelle A; Voisin AL; Mateus C; Rémond AL; Couret C; Champiat S; Labetoulle M; Rousseau A
Am J Ophthalmol; 2019 Jun; 202():109-117. PubMed ID: 30772350
[TBL] [Abstract][Full Text] [Related]
36. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
38. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
39. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
[TBL] [Abstract][Full Text] [Related]
40. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
Cassol CA; Owen D; Kendra K; Braga JR; Frankel WL; Arnold CA
Histopathology; 2020 Aug; 77(2):240-249. PubMed ID: 32298485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
